The results of the study showed a confirmed objective response rate of 14%. Patients with metastatic squamous cell carcinoma have poor five-year survival and there are no standard treatment for patients who have progressed after chemotherapy, according to a news release.
The drug candidate was also found to be well-tolerated.
Price: 90.42, Change: +0.48, Percent Change: +0.53
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|